Overview
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Status:
Recruiting
Recruiting
Trial end date:
2022-03-01
2022-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A randomized active-controlled multi-site double-masked study to evaluate the safety and tolerability of 2 concentrations of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucomaPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Qlaris Bio, Inc.
Criteria
Inclusion Criteria:1. Visual acuity +1.0 logMAR or better
2. Willing to give informed consent
3. Ability to washout from current intraocular pressure lowering medications -
Exclusion Criteria:
1. All secondary glaucomas
2. Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty
permitted when done 18 months or longer from Screening)
3. Refractive surgery
4. Ocular infection or inflammation